Search hospitals > Oregon > Portland
OHSU Knight Cancer Institute
Claim this profilePortland, Oregon 97239
Global Leader in Leukemia
Global Leader in Cancer
Conducts research for Breast Cancer
Conducts research for Tumors
Conducts research for Prostate Cancer
427 reported clinical trials
52 medical researchers
Summary
OHSU Knight Cancer Institute is a medical facility located in Portland, Oregon. This center is recognized for care of Leukemia, Cancer, Breast Cancer, Tumors, Prostate Cancer and other specialties. OHSU Knight Cancer Institute is involved with conducting 427 clinical trials across 392 conditions. There are 52 research doctors associated with this hospital, such as Lara Davis, MD, Zahi Mitri, Shivaani Kummar, MD, and Jeremy P. Cetnar.Area of expertise
1Leukemia
Global LeaderJAK2 positive
BCR-ABL1 positive
t(9;22) translocation positive
2Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Lara Davis, MDOHSU Knight Cancer Institute4 years of reported clinical research
Studies Sarcoma
Studies Tumors
15 reported clinical trials
45 drugs studied
Zahi MitriOHSU Knight Cancer Institute1 year of reported clinical research
Expert in Breast Cancer
Studies Cancer
15 reported clinical trials
37 drugs studied
Shivaani Kummar, MDOregon Health and Science University1 year of reported clinical research
Studies Solid Tumors
Studies Colorectal Cancer
12 reported clinical trials
19 drugs studied
Jeremy P. CetnarOregon Health and Science University5 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
11 reported clinical trials
23 drugs studied
Clinical Trials running at OHSU Knight Cancer Institute
Breast Cancer
Pancreatic Cancer
Cancer
Leukemia
Acute Myeloid Leukemia
Rectal Cancer
Prostate Cancer
Tumors
Head and Neck Cancers
Brain Tumor
BAL0891 + Chemotherapy
for Solid Tumors
This trial tests a new drug, BAL0891, given to patients with severe cancer. It aims to find a safe and effective amount, both alone and with other cancer treatments. The goal is to determine the best amount that patients can handle.
Recruiting1 award Phase 1
Counseling with Pictorial Aid
for Breast Cancer
This clinical trial studies the effect of standard verbal counseling with or without a pictorial educational tool for the reduction of psychological morbidity in patients with stage 0-IIIA breast cancer receiving radiation therapy. Beginning radiation therapy for breast cancer can be stressful. Education about what to expect often reduces the stress, anxiety, and depression experienced by these patients. This study is being done to see how effective photos are in reducing stress, anxiety, and depression associated with radiation therapy for patients with breast cancer.
Recruiting1 award N/A2 criteria
Combination Therapy
for Triple Negative Breast Cancer
This phase II study assesses the efficacy of the combination of olaparib with durvalumab, selumetinib, or capivasertib or ceralasertib alone in the treatment of patients with metastatic triple negative breast cancer (TNBC). Olaparib may stop growth of tumor cells by inhibiting some of the enzymes (ADP ribose polymerase \[PARP\]) needed for cell growth. Durvalumab, a monoclonal antibody, inhibits the growth and spread of tumors by stimulating the patient's antitumor immune response. Selumetinib, capivasertib, and ceralasertib are inhibitor drugs that may stop the growth of tumor cells by blocking some of the enzymes (MEK, AKT, ATR) needed for cell growth. Giving olaparib together with durvalumab, selumetinib, or capivasertib or giving ceralasertib alone may provide an effective method to treat patients with metastatic triple negative breast cancer.
Recruiting1 award Phase 215 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at OHSU Knight Cancer Institute?
OHSU Knight Cancer Institute is a medical facility located in Portland, Oregon. This center is recognized for care of Leukemia, Cancer, Breast Cancer, Tumors, Prostate Cancer and other specialties. OHSU Knight Cancer Institute is involved with conducting 427 clinical trials across 392 conditions. There are 52 research doctors associated with this hospital, such as Lara Davis, MD, Zahi Mitri, Shivaani Kummar, MD, and Jeremy P. Cetnar.
Where is OHSU Knight Cancer Institute located?
The OHSU Knight Cancer Institute is situated on the South Waterfront campus in Portland, OR, located at 3181 S W Jackson Park Rd, Portland, OR 97239.
Who should I call to ask about financial aid or insurance network?
**OHSU Knight Cancer Institute Financial Assistance:**
- For assistance with medical care costs at OHSU, Hillsboro Medical Center, and Adventist Health Portland, contact 503-494-8551 (Mon-Fri, 8 a.m. to 4:30 p.m. PT).
- Eligibility includes those without health insurance, insufficient health insurance, or qualifying for state/federal assistance.
**OHSU Knight Cancer Institute Insurance Department:**
- For billing and insurance inquiries, call 866-617-6855.
- This contact serves all OHSU Health hospitals and clinics for general billing and insurance questions, excluding some professional charges.
What insurance does OHSU Knight Cancer Institute accept?
The OHSU Knight Cancer Institute accepts a wide range of insurance plans, including but not limited to Aetna, CareOregon, Cigna, Health Net, Humana, Kaiser Permanente, Moda, Molina Healthcare, PacificSource, Providence Health Plan, Regence BlueCross BlueShield, and TriWest HealthCare Alliance. They also accept original Medicare, known as traditional Medicare. It's important to verify coverage with your insurance provider before receiving care.
What awards or recognition has OHSU Knight Cancer Institute received?
The OHSU Knight Cancer Institute, located in Portland, Oregon, is a National Cancer Institute-designated Comprehensive Cancer Center. This prestigious recognition places it among the nation's elite for laboratory and clinical research, community service, and multidisciplinary scientific research. It is also an active member of global cancer organizations and networks, positioning it at the forefront of cancer research and care.